Release date: 2016-11-21 t:slim X2 insulin pump Dexcom and Tandem Diabetes Care, which specialize in diabetes, are working with digital health company TypeZero Technologies to develop a closed-loop system for blood glucose control. The system will include Dexcom's G5 glucose sensor, tandem insulin pump and smartphone, which will run TypeZero's inControl closed-loop algorithm. According to the statement, the joint platform will continue to detect blood sugar levels and automatically adjust the delivery of insulin. While the primary purpose of the system is to modulate the base or inject insulin, the system is also capable of automating the correction and may also allow the user to autonomously replenish the corresponding dose of insulin prior to the meal. It will be tested in the International Diabetes Closed Loop trial, which is funded by the National Institutes of Health (NIH) and will begin later this year. The experimenter hopes to recruit 240 adult patients with type 1 diabetes for the trial. Boris Kovatchev, director and lead researcher at the University of Virginia Diabetes Technology Center, said: "The IDCL trial is a key experiment in a closed-loop control system, including seven institutions from the US led by the University of Virginia and three European institutions. In the trial, Tandem, Dexcom and TypeZero provided related technology integration, which represents a new level of development in artificial pancreas research and development." Although the closed-loop system can run the “inControl algorithm†on current smartphones, the designer hopes to integrate Dexcom's G6 sensor into Tandem's t:slim X2 insulin pump and directly embed the TypeZero algorithm into the The insulin pump's touch screen is used in combination. Partners expect to introduce this new design into trial and implementation in 2017, and they expect the technology to be key to the submission of future regulatory reviews along with the trial data. Currently, there is an approved "artificial pancreas" on the market, a hybrid closed-loop system from Medtronic, which was approved by the FDA in September this year. The artificial pancreas is suitable for patients with type 1 diabetes who are 14 years of age and older and can adjust the background insulin level of the patient by "small input" or "no input" of insulin. The system consists primarily of Medtronic's MiniMed 670G insulin pump, infusion patches and catheters that regulate insulin delivery, and sensors that continuously monitor subcutaneous sugar levels. Source: Sina Pharmaceutical News A seedbed or seedling bed is the local soil environment in which seeds are planted. Often it comprises not only the soil but also a specially prepared cold frame, hotbed or raised bed used to grow the seedlings in a controlled environment into larger young plants before transplanting them into a garden or field. A seedling bed is used to increase the number of seeds that germinate. Greenhouse Seedling Bed,Stainless Greenhouse Seedling Bed,Greenhouse Seedling Nursery Bed JIANGSU SKYPLAN GREENHOUSE TECHNOLOGY CO.,LTD , https://www.engreenhouse.com
NIH supports three companies to jointly develop the "artificial pancreas" test
Prev Article
The cause and prevention of cucumber melon deformity